Drugs / AZD1705
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06238466 Comparator | Jan 2024 → Dec 2025 overdue | cardiovascular disorder | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238466 ↗ |
| Route | Subcutaneous | “Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.” NCT06238466 ↗ |